A recent study showed a remarkable benefit in women with stage I to III HER2-positive breast cancer with residual disease after neoadjuvant chemotherapy plus trastuzumab and treated in the postoperative period with trastuzumab-emtansine when compared to those that were treated with trastuzumab [95]. The gene discussed is ERBB2; the disease is breast cancer.